Source: International Congress 2017 – Management of COPD
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
S. Chen (Gaithersburg, United States of America). Symptomatic burden of COPD for patients receiving dual or triple therapy. 3246

Member's Comments

No comment yet.

Related content which might interest you: Triple therapy for all patients with severe symptomatic COPD at risk of exacerbations Source: Eur Respir J, 53 (4) 1900147; 10.1183/13993003.00147-2019 Year: 2019 Single-inhaler triple therapy in symptomatic COPD patients: FULFIL subgroup analyses Source: ERJ Open Res, 4 (2) 00119-2017; 10.1183/23120541.00119-2017 Year: 2018 Extrafine triple therapy in patients with symptomatic COPD and history of one moderate exacerbation Source: Eur Respir J, 53 (5) 1900235; 10.1183/13993003.00235-2019 Year: 2019 Single inhaler triple therapy in advanced COPD patients: prior medication and disease severity FULFIL subanalyses Source: International Congress 2017 – COPD management Year: 2017 Preventing clinically important deterioration with single-inhaler triple therapy in COPD Source: ERJ Open Res, 4 (4) 00047-2018; 10.1183/23120541.00047-2018 Year: 2018 Effect of ICS withdrawal on COPD exacerbations in patients on triple therapy at baseline Source: International Congress 2018 – COPD management Year: 2018 Clinical and economic impact of inhaled corticosteroid withdrawal in Spanish COPD patients treated with triple therapy Source: Virtual Congress 2021 – Inhaled treatments for COPD: clinical trials and real-world studies Year: 2021 Economic impact of delayed multiple-inhaler triple therapy initiation in COPD patients Source: Virtual Congress 2020 – Pharmacological management of COPD Year: 2020 Burden of disease among exacerbating patients with eosinophil COPD treated with triple therapy in Spain Source: Virtual Congress 2020 – COPD : inhaled corticosteroids, bronchodilators and eosinophils Year: 2020 The IMPACT of triple versus dual single-inhaler therapy on exacerbations of COPD Source: Breathe, 14 (4) 333; 10.1183/20734735.026418 Year: 2018 Cost consequences of tiotropium plus existing therapy versus existing therapy alone following one year of treatment in patients with COPD Source: Eur Respir J 2001; 18: Suppl. 33, 5s Year: 2001 Influence of statin therapy on exacerbation frequency in patients with COPD Source: Annual Congress 2009 - Drug effects in COPD Year: 2009 Economic evaluation of the impact of exacerbation frequency in COPD patients treated with single-inhaler triple therapy in Spain: The IMPACT trial Source: Virtual Congress 2020 – Pharmacological management of COPD Year: 2020 Cost burden in COPD patients initiating ICS vs. non-ICS maintenance regimens Source: International Congress 2019 – How to guide patients to reach a balance between costs and personal needs: quality indicators of effectiveness Year: 2019 Efficacy of traditional and combined therapy in patients with sarcoidosis Source: Eur Respir J 2003; 22: Suppl. 45, 234s Year: 2003 Single inhaler triple therapy in patients with advanced COPD (FULFIL): exacerbation/pneumonia composite outcomes Source: International Congress 2017 – COPD management Year: 2017 Comparative effectiveness of two different doses of inhaled corticosteroid in triple therapy on exacerbations in patients with severe COPD: a real-world study Source: Virtual Congress 2021 – Therapies for respiratory diseases in primary care and COVID - 19 Year: 2021 Clinically important deterioration in advanced COPD patients using single inhaler triple therapy: results from the FULFIL study Source: International Congress 2017 – Management of COPD Year: 2017 Chinese subgroup results from a study comparing single-inhaler triple therapy with dual therapy in COPD Source: International Congress 2017 – COPD management Year: 2017 Is there a benefit of an additive standard immunoglobulin therapy for the clinical course of COPD patients under chronic immunosuppressive therapy? Source: Eur Respir J 2001; 18: Suppl. 33, 24s Year: 2001